HRMY News and Press, Harmony Biosciences Holdings Inc. From 04/30/24

2024-04-30 07:14:12 ET More on Harmony Biosciences Harmony Biosciences Holdings, Inc. (HRMY) Q4 2023 Earnings Call Transcript Harmony Biosciences Q1 2024 Earnings Preview Harmony inks licensing deal for sleep disorder therapy Seeking Alpha’s Quant Rati...

WAKIX ® (pitolisant) Net Revenue of $154.6 Million for First Quarter 2024; ~30% Growth Year-over-Year Supplemental New Drug Application for Pitolisant in Idiopathic Hypersomnia Planned for Second Half 2024 On Track Toward Pediatric Exclusivity to Extend WAKIX Exclusivit...

LPL Financial Holdings Inc. (LPLA) is expected to report $3.77 for Q1 2024 Banco Santander Brasil SA American Depositary Shares each representing one unit (BSBR) is expected to report $0.14 for Q1 2023 EnLink Midstream LLC representing Limited Partner Interests (ENLC) is expected to repor...

Harmony Biosciences Acquires Epygenix Therapeutics, Inc., Adding Late-Stage Epilepsy Franchise to Growing Pipeline of Innovative CNS Assets PR Newswire Lead Candidate, EPX-100, Holds Orphan Drug and Rare Pediatric Disease Designations EPX-100 in Pivotal Registrational ...

2024-04-29 13:26:57 ET More on Harmony Biosciences Harmony Biosciences Holdings, Inc. (HRMY) Q4 2023 Earnings Call Transcript Harmony inks licensing deal for sleep disorder therapy Harmony Biosciences Non-GAAP EPS of $0.73 misses by $0.18, revenue of $168.4M in-line ...

2024-04-29 11:15:34 ET Major earnings expected before the bell on Tuesday include: Enterprise Products Partners ( EPD ) The Coca-Cola ( KO ) McDonald's ( MCD ) 3M Company ( MMM ) PayPal Holdings ( PYPL ) Read the full article on Seeking Alph...

2024-04-16 16:24:42 ET Summary The healthcare sector is overvalued by 14% based on 11-year averages. Healthcare providers are not far from their valuation baseline, while the most overvalued subsector is healthcare equipment. Fast facts on Fidelity MSCI Health Care Index ETF, ...

HARMONY BIOSCIENCES TO REPORT FIRST QUARTER 2024 FINANCIAL RESULTS ON APRIL 30, 2024 PR Newswire PLYMOUTH MEETING, Pa. , April 16, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report first quarter 2024 f...

2024-04-11 12:36:36 ET More on Harmony Biosciences Harmony Biosciences Holdings, Inc. (HRMY) Q4 2023 Earnings Call Transcript Harmony Biosciences Non-GAAP EPS of $0.73 misses by $0.18, revenue of $168.4M in-line Harmony Biosciences Q4 2023 Earnings Preview Se...

HARMONY BIOSCIENCES ANNOUNCES EXCLUSIVE AGREEMENT TO DEVELOP AND COMMERCIALIZE TPM-1116, A HIGHLY POTENT AND SELECTIVE ORAL OREXIN-2 RECEPTOR AGONIST TPM-1116 preclinical data suggest a potential best-in-class profile that could transform the treatment of narcolepsy and other sleep/wake...